Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study
ConditionProstate Carcinoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age40+
SponsorUniversity of Washington
About this trial
This study investigates ways to detect prostate cancer earlier in people at genetic risk for disease that forms, grows, or spreads quickly (aggressive). Studying samples of blood, urine, and/or tissue in the laboratory may help doctors further understand the genetics of prostate cancer and help identify ways to detect cancer earlier, thereby improving treatment and methods of early detection in the future.
Eligibility criteria
Qualifiers
People with prostates ≥40 years of age
Documented germline pathogenic variant in known or suspected genes associated with prostate cancer risk.
Disqualifiers
Prior diagnosis of prostate cancer
Medical contraindication to any of the study procedures (e.g., prostate biopsy)
For all cancer types except non-melanoma skin cancer, any cancer treatment with curative intent within the past 12 months (e.g., surgery, radiation, chemotherapy, immunotherapy)
Prior or concurrent participation in an interventional clinical trial aimed at preventing cancer for people with germline variants associated with increased prostate cancer risk
Trial design
Treatments tested in this trial
- Biospecimen Collection
- Laboratory Biomarker Analysis
- Quality-of-Life Assessment
- Questionnaire Administration
Treatment groups
450 Participants
are divided into 1 treatment groupLocations
8California
City of Hope91010, Duarte United States
University of California, San Francisco94143, San Francisco United States
Illinois
Northwestern60611, Chicago United States
Massachusetts
Massachusetts General Hospital02114, Boston United States
Sponsors and collaborators
University of Washington
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Canary Foundation
Collaborator
CureBRCA
Collaborator
Source ClinicalTrials.gov